Results 61 to 70 of about 3,591 (213)

The double bronchodilation era: new capabilities in a new drug delivery device

Медицинский совет, 2022
A literature review presents the efficacy and safety of the new glycopyrronium bromide/formoterol fumarate (GP/FF) combination in the treatment of patients with chronic obstructive pulmonary disease according to the PINNACLE 1, 2, 3, 4 studies. There are
E. A. Orlova, I. P. Dorfman, M. A. Orlov, M. A. Abdullaev   +3 more
doaj   +1 more source

Impact of Mechanistic Modeling and Simulation Methodologies on Product‐Specific Guidance Development for Non‐Orally Administered Drug Products

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 9, Page 1421-1430, September 2025.
ABSTRACT The U.S. Food and Drug Administration (FDA) publishes product‐specific guidances (PSGs), with bioequivalence (BE) recommendations for prospective generics. Developing BE recommendations for non‐orally administered drug products including long‐acting injectables (LAI), orally inhaled drug products, and drugs applied locally to the skin ...
Steven G. Chopski, Ross L. Walenga, Ming‐Liang Tan, Khondoker Alam, Andrew Babiskin, Lanyan Fang, Eleftheria Tsakalozou   +6 more
wiley   +1 more source

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD

International Journal of COPD, 2018
Gary T Ferguson,1 Roberto Rodriguez-Roisin,2 Colin Reisner,3,4 Andrea Maes,3 Shahid Siddiqui,4 Ubaldo J Martin4 1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2Universitat de Barcelona, Hospital Clínic-The August ...
Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ   +5 more
doaj  

Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial

BMC Pulmonary Medicine, 2012
Background This study investigated the efficacy and safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform®), administered twice daily (b.i.d.) via a single aerosol inhaler, compared ...
Nathan Robert A, D’Urzo Anthony, Blazhko Viktor, Kaiser Kirsten   +3 more
doaj   +1 more source

COPD: Optimizing Treatment [PDF]

, 2015
A guideline update and an expanded armamentarium have many physicians wondering how best to treat patients with COPD. Chronic obstructive pulmonary disease (COPD) carries a high disease burden. In 2012, it was the 4th leading cause of death worldwide.1,2
Ahmed-Sarwar, Nabila, Holub, David C, Pierce, Deirdre P   +2 more
core   +1 more source

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review) [PDF]

, 2009
Background Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are ...
Cates, CJ, Jaeschke, R, Lasserson, TJ
core   +1 more source

Comparison of aerosol formulations of formoterol fumarate and budesonide.

Indian journal of pharmaceutical sciences, 2011
The aerodynamic diameter of pharmaceutical aerosols is the main factor governing their deposition in the human respiratory tract. Particle size of the pharmaceutical aerosols is characterized by liquid impingers and Andersen Cascade Impactors. The present study was aimed at comparing two metered dose inhaler formulation containing formoterol fumarate ...
Nirale, N. M., Nagarsenker, M. S., Mendon, S. B., Chanagare, R., Katkurwar, A., Lugade, V.   +5 more
openaire   +2 more sources

Pharmacokinetics (PK) and safety of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) and glycopyrronium/formoterol fumarate dihydrate (GFF) metered dose inhaler (MDI) in healthy Chinese adults [PDF]

Airway pharmacology and treatment, 2018
Introduction and objectives: BGF MDI is an ICS/LAMA/LABA fixed-dose combination (FDC) in late-stage clinical development for COPD formulated using innovative co-suspension delivery technology. We assessed the PK profile (primary objective) and safety/tolerability (secondary objective) of two doses of BGF MDI and the LAMA/LABA FDC, GFF MDI, in healthy ...
Hanna Yu, Yun Liu, Kevin Shen, Pryseley N. Assam, Michael Gillen, Paul Dorinsky   +5 more
openaire   +3 more sources

Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways

British Journal of Pharmacology, Volume 182, Issue 17, Page 4122-4133, September 2025.
Abstract Background and Purpose Increased contractility of human airway smooth muscle (hASM) is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Developing new classes of bronchodilators has proved to be challenging because of efficacy and safety concerns.
Paola Rogliani, Clive Page, Francesco Facciolo, Mia Lundblad, Luigino Calzetta   +4 more
wiley   +1 more source

Management of Primary Ciliary Dyskinesia in a Kartagener's Syndrome Patient With Total Situs Inversus

Respirology Case Reports, Volume 13, Issue 8, August 2025.
We report the case of a 62‐year‐old female patient with complete situs inversus of the chest and abdominal organs. Bronchoscopic washout of the lungs was performed for therapeutic benefit and culturing for targeted antibacterial therapy. This case highlights the importance of a comprehensive and effective management approach for patients with ...
Ivan H. Huang, Kenneth N. Dang, Saarang Kashyap, Alexander J. Sweidan   +3 more
wiley   +1 more source